Manchester Molecular Pathology Innovation Centre (MMPathIC): bridging the gap between biomarker discovery and health and wealth

Lead Research Organisation: University of Manchester
Department Name: School of Biological Sciences

Abstract

Stratified medicine (which is allied to personalised or precision medicine) is an approach to treating patients through categorising them into groups based on their risk of developing a particular disease, or how they are likely to respond a particular drug or therapy.

It is key that the correct tests and techniques are available which can put individuals into groups (stratify patients), depending on their exact disease type and likely response to particular treatments. One way in which this might be possible is by application of molecular pathology, a specific type of pathology ( which is the study of disease), focused on the diagnosis and repeated characterisation of disease through the examination of molecules within organs, tissues or bodily fluids, such as blood, urine or synovial fluid (the fluid found in joints).

The aim of the Manchester molecular pathology node (Manchester Molecular Pathology Innovation Centre- MMPathIC) is to create an environment which enables new tests, based on molecular pathology techniques, to be developed. These can then be used to stratify patients, to allow more accurate diagnosis or prediction of the best treatments to use. As we already have significant groups of patient samples from people who suffer from inflammatory disease (psoriasis, rheumatoid arthritis and lupus), we will focus on these diseases in the first instance. These diseases are also important as, between them, they affect a large part of our population, treatment can be expensive (and often doesn't work first time, meaning patients have to try a number of expensive drugs before getting any relief from their symptoms), and these diseases often severely affect a person's quality of life due to pain and discomfort. In addition, we are going to build upon the lessons already learned in this area from our established expertise in cancer molecular pathology, which is far further developed in the provision of targeted therapies.

We will look at samples from patients with these inflammatory diseases, using a new technique that supports the measurement of many proteins within a minimally invasive sample (such as blood, urine or tissue). This will allow differences between samples from, for example, healthy people and people with a specific disease, to be examined- differences in certain proteins may prove useful as biomarker tests which can be used to diagnose a disease. In addition, by examining the differences in the levels of particular marker proteins from patients who respond to a drug compared to those who don't respond, doctors will be able to identify which drug is the best treatment for specific patients. This will hopefully have economic benefit as drugs will not be used on patients who will receive no benefit from them, but MMPathIC will ensure there is economic benefit through undertaking health economic analysis of potential markers- this will also allow informed decisions to be made by NHS officials who have to make decisions about which tests are viable for introduction into the health service.

As we can measure these proteins, we also propose ensuring that this data is linked to genomic data (the blueprint for these building blocks that are proteins) and health records- this integration will be facilitated by MMPathIC's staff, which will include skilled information specialists who can make sense of the data produced and data which already exists (data mining).

In collaboration with industry (who have the expertise to commercialise new tests, and navigate the necessary regulatory hurdles), we aim to produce at least 6 new tests which are ready to be commercialised, or ready to be used in hospital pathology laboratories in the first 3 years of the grant

Technical Summary

Our aim is to establish an infrastructure: promoting biomarker discovery; translation into molecular pathology tests; NHS dissemination; and commercialisation.
-Discovery builds on existing strengths in "omics" technologies (notably £13M MRC Clinical Proteomics Centre [MRC-CPC], North West Genomic Medicine Centre [NW-GenMed]); University of Manchester's (UoM) Health Economics/Biostatistics, UoM TextMining (NaCTeM); Farr Institute safe haven for data analysis; and MIMIT (Manchester Integrating Medicine and Innovative Technology)
-Translation exploits the molecular pathology expertise across Central Manchester Foundation Trust's (CMFT) extensive laboratories and UoM's Experimental Molecular Pathology.
-Dissemination utilises interlinked NW networks of pathology laboratories, facilitated by Greater Manchester Academic Health Sciences Network (GM-AHSN)
-Commercialisation will develop around the partners' intellectual property commercialisation agents (UMI3, Trustech); commercial partners; and through Innovate's UK Precision Medicine Catapult (IUK PM Catapult)
All activities benefit from Manchester Academic Health Sciences Centre's (MAHSC) £3bn healthcare economy; UoM health economists; involvement of NICE and patient groups; local educational resource; and links with other nodes.
Ultimately we will produce an infrastructure for developing biomarker-based molecular pathology tests for many diseases, but initially we concentrate on key inflammatory pathways for diagnosing, stratifying and assessing therapeutic response of patients within our 3 MRC Stratified Medicine Programmes (MRC-StratMedP: MATURA £5.7M, rheumatoid arthritis [RA]; MASTERPLANS £5.1M, lupus; PSORT £5M, psoriasis)
A major MMPathIC activity is developing generic pipelines encompassing discovery and translation to GCLP standards. This we will pursue in intellectual partnership and shared complimentary resources with colleagues in CRUK's Major Cancer Centre to optimise time and cost effectiveness

Planned Impact

Patients- will benefit from improved diagnostics, and new clinical tests which can predict prognosis and likelihood of response to specific treatments. Patients will be more fully informed about their condition at an earlier stage, diagnosed more quickly and be offered treatment sooner that is appropriate for the precise molecular nature of their disease, reducing the likelihood of adverse drug reactions, side effects, and the need to try multiple therapies before disease control is achieved. Morbidity and mortality will be reduced, patient safety and outcomes will be improved, with resultant effects on quality of life, and work days lost to illness.
Commissioners and policy makers- will be able to make informed choices about the indications for new and existing therapies. Clinicians can make smarter decisions about disease management and courses of treatments.
NHS- will save money through a quicker route to diagnosis, a reduction in invasive diagnostic procedures, and improved pathology and laboratory medicine services. This will reduce the necessity of inappropriate or aggressive treatment, and in turn, the economic burden of disease on the health service
Industry- MMPathIC will provide a pipeline of biomarkers which will be of potential interest for companies working in the diagnostic field to develop further into useable, marketable tests. New diagnostics for common conditions which make it into routine service have potential to produce significant revenue. The pharmaceutical industry will benefit from being able to implement improved clinical trial performance based on improved classification of patients, thus improving statistical significance and the likelihood of success of targeted therapies. Additionally, the node will provide infrastructure (both physical facilities and intellectual expertise), which smaller commercial companies can access (eg GCLP facility for protein biomarkers, health economist support, amongst others) which they don't have the capacity to provide in-house. MMPathIC will allow access to a test-bed regionally via GM AHSN (a potential population of 3M), and nationally via the wider node network. This represents a significant opportunity for industry who wish to demonstrate clinical and commercial proof of concept, and access to biobanks, patient cohorts and electronic health records. These benefits have the potential to be synergistic- smaller biotech and diagnostic companies will benefit from increased use of molecular diagnostics, and the opportunities this will bring in terms of companion diagnostic development alongside pharma's targeted therapies. Likewise, MMPathIC industry partners, through Manchester hub and the network model proposed by linkage with other UK nodes, will foster new links with other businesses working in this sphere, and potentially act as expert suppliers and service providers to each other, and collaborate via risk-sharing agreements.
Charities- will benefit from MMPathIC results and outputs through being able to tailor their translational research programmes accordingly. Charity-funded projects will be able to access the facilities of the node, representing value for money and cost-sharing (rather than replicating or duplicating resources on individual projects).
Clinical scientists- will benefit through the increased capacity to undertake discovery biomarker projects (through CPC and other infrastructure encompassed within, or accessible via, the MMPathIC molecular pathology node), which involve the most appropriate expertise in terms of validation, verification and informatics, from the outset. The development of a Pathology Masters in Research, based on our successful intercalated BSc, will increase capacity and allow the embedding of molecular pathology approaches across the clinical specialities. This will be complemented, through GM AHSN, by an increased awareness of molecular pathology across the health service workforce, across clinical/ non-clinical roles
 
Description Future of Immunology, Houses of Parliament, London - October 2018. Meeting to promote immunology across Government, M/S, Charities and British Society of Immunology
Geographic Reach National 
Policy Influence Type Participation in a national consultation
 
Guideline Title Guideline on drug monitoring in rheumatoid arthritis
Description Lead Specialist Committee member on NICE Diagnostic Advisory Committee
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Description Life Sciences Review, House of Lords, London - October 2018 Hosted by Randox Laboratories
Geographic Reach National 
Policy Influence Type Participation in a national consultation
 
Description MRC Workshop on Methodology for Stratified Medicine - July 2015. 'Stratum Verification'
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
 
Description UK Biobank Enhancement Working Group
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
 
Description "Biomarkers in urine, anyihypertensive treatment and blood pressure control in hypertensive patients - outreach study"
Amount £754,472 (GBP)
Funding ID CS/17/3/32799 
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2017 
End 08/2020
 
Description AI and digital pathology
Amount £10,000,000 (GBP)
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 03/2019 
 
Description Accounting for multimorbidity competing risk and direct treatment disutility in risk prediction tools and model-based cost-effectiveness analysis for the primary prevention of cardiovascular disease and osteoporotic fracture
Amount £689,784 (GBP)
Funding ID HS&DR/15/12/22 
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 09/2016 
End 08/2019
 
Description Airway remodelling in chronic airways disease
Amount £4,200 (GBP)
Organisation Pathological Society of Great Britain & Ireland 
Sector Learned Society
Country United Kingdom
Start 12/2017 
End 01/2019
 
Description BiOmarkers in Urine, anTihypeRtensive trEAtment and blood pressure Control in Hypertensive patients - OUTREACH Study
Amount £754,472 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2017 
End 09/2020
 
Description CLUSTER: Childhood arthritisand its associated uveitis: stratification through endotypes and mechanisms to deliver benefit
Amount £5,000,000 (GBP)
Funding ID MR/R013926/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 07/2018 
End 06/2023
 
Description Chromition: Use of a novel biomarker disclosing system for multiplexed tissue immunohistochemistry
Amount £1,100,000 (GBP)
Funding ID https://sbrihealthcare.co.uk/news/sbri-healthcare-fast-tracks-cancer-diagnostic-inventions-with-3-8m-funding/ 
Organisation Small Business Research Initiative (SBRI) 
Sector Public
Country Unknown
Start 01/2018 
End 09/2019
 
Description DeepMedIO: Digital pathology and AI for detecting cancer lymph node depositis
Amount £1,100,000 (GBP)
Funding ID https://sbrihealthcare.co.uk/news/sbri-healthcare-fast-tracks-cancer-diagnostic-inventions-with-3-8m-funding/ 
Organisation Small Business Research Initiative (SBRI) 
Sector Public
Country Unknown
Start 01/2018 
End 09/2019
 
Description Fight for Sight PhD Studentship
Amount £98,768 (GBP)
Funding ID 2033 
Organisation Fight for Sight 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2019 
End 09/2022
 
Description Generating evidence to support the use of stratified medicine for the treatment of people with lupus
Amount £78,706 (GBP)
Organisation LUPUS UK 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2016 
End 05/2019
 
Description Immune-Mediated Inflammatory Disease Biobanks in the UK (IMIDBio-UK)
Amount £1,700,000 (GBP)
Funding ID MR/R014191/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 09/2017 
End 03/2021
 
Description MICA: NURTuRE - changing the landscape of renal medicine to foster a unified approach to stratified medicine
Amount £2,561,603 (GBP)
Funding ID MR/R013942/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 07/2018 
End 07/2022
 
Description Manchester Coronary Artery Disease
Amount £160,000 (GBP)
Organisation Singulex, Inc. 
Sector Private
Country United States
Start 05/2018 
End 11/2019
 
Description Methotrexate use improvement in Rheumatoid Arthritis using Biomarker Feedback (MIRA): a feasibility trial
Amount £12,000 (GBP)
Organisation Association of Physicians of Great Britain and Ireland 
Sector Learned Society
Country United Kingdom
Start 09/2018 
End 08/2019
 
Description NIHR Common Disease BioResource
Amount £900,000 (GBP)
Organisation University of Cambridge 
Sector Academic/University
Country United Kingdom
Start 01/2019 
End 03/2022
 
Description NURTuRE: Changing the landscape of renal medicine to foster a unified approach to stratified medicine
Amount £3,100,000 (GBP)
Funding ID MR/R013942/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 07/2018 
End 06/2023
 
Description OUTREACH: Biomarkers in urine, anti-hypertensive treatment and blood pressure control in hypertensive patients
Amount £745,000 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2018 
End 02/2021
 
Description The Pre-hospital Evaluation of Sensitive Troponin (PRESTO) study
Amount £338,089 (GBP)
Funding ID PB-PG-1216-20034 
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 08/2018 
End 01/2020
 
Title A Dashboard for Latent Class Trajectory Modelling: application in Rheumatoid Arthritis 
Description Given the complex nature of Rheumatoid Arthritis (RA), identification of patient subgroups with variable response patterns to therapy would facilitate a precision medicine approach for the treatment of RA. Here we provide an overview on the implementation and the use of dashboards in clinical research. Specifically, using R Shiny, we developed an app which enables data patterns exploration for clinicians. We applied latent class mixed modelling (LCMM) to identify patient subgroups which display differential change in disease severity over time and provide a dashboard to allow for exploration of results of this modelling approach. Real time representation of the status of a cohort of patients will better support clinical decision and provide a start point for research. Our dashboard provides an initial step and prototype for this. 
Type Of Material Improvements to research infrastructure 
Year Produced 2018 
Provided To Others? No  
Impact None yet 
 
Title APLenty: annotation tool for creating high-quality datasets using active and proactive learning 
Description APLenty, is an annotation tool for creating high-quality sequence labeling datasets using active and proactive learning. A major innovation of this tool is the integration of automatic annotation with active learning and proactive learning. This makes the task of creating labeled datasets easier, less time-consuming and requiring less human effort. APLenty is highly flexible and can be adapted to various tasks such as database curation and information extraction 
Type Of Material Improvements to research infrastructure 
Year Produced 2018 
Provided To Others? Yes  
Impact Several groups are using it to create labelled data for training 
URL http://www.nactem.ac.uk/aplenty/
 
Title Inferring Temporal Phenotypes with Topological Data Analysis and Pseudo Time-Series 
Description Temporal phenotyping enables clinicians to better under-stand observable characteristics of a disease as it progresses. Modelling disease progression that captures interactions between phenotypes is inherently challenging. Temporal models that capture change in disease over time can identify the key features that characterize disease sub-types that underpin these trajectories. These models will enable clinicians to identify early warning signs of progression in specific sub-types and therefore to make informed decisions tailored to individual patients. In this paper, we explore two approaches to building temporal phenotypes based on the topology of data: topological data analysis and pseudo time-series. Using type 2 diabetes data, we show that the topological data analysis approach is able to identify trajectories representing different temporal phenotypes and that pseudo time-series can infer a state space model characterized by transitions between hidden states that represent distinct temporal phenotypes. Both approaches highlight lipid profiles as key factors in distinguishing the phenotypes. Research method developed by Arianna Dagliati in collaboration with Allan Tucker (Brunel University London) & John H. Holmes (University of Pennsylvania, Philadelphia) & Lucia Sacchi (University of Pavia, Italy) 
Type Of Material Improvements to research infrastructure 
Year Produced 2018 
Provided To Others? No  
Impact None yet 
 
Description Evaluation of the Singulex Clarity immunoassay platform in the diagnosis of myocardial infarction. 
Organisation Singulex, Inc.
Country United States 
Sector Private 
PI Contribution We are evaluating this new platform in the early "rule out" f myocardial disease in A&E patients. We are contributing clinical and laboratory expertise and well characterised patient groups.
Collaborator Contribution They have provided the platform ($250000) and consumables ($150000) together with technical expertise
Impact There are no formal outputs yet, but we are accumulating data currently. An initial health economic analysis of early data suggests a potential saving to the NHS of about £20M a year in NHS bed days.
Start Year 2016
 
Description NIHR BioResource 
Organisation University of Leeds
Department Leeds Institute of Rheumatic and Musculoskeletal Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution We led a collaborative Common Diseases BioResource for Immune Mediated Inflammatory Diseases
Collaborator Contribution MAnchester BRC will be the co-ordinating partner in the Common Disease BioResource for IMID
Impact N/A
Start Year 2019
 
Description NIHR Common Disease BioResource 
Organisation Newcastle University
Country United Kingdom 
Sector Academic/University 
PI Contribution We led a collaborative Common Diseases BioResource for Immune Mediated Inflammatory Diseases
Collaborator Contribution Manchester BRC will co-ordinate the Common Disease BioResource for Immune Mediated Inflammatory Diseases
Impact None as yet
Start Year 2019
 
Title Thalia: a faceted semantic search system 
Description The main purpose of Thalia is to enable semantic search in the context of biomedical literature by leveraging previous named entity (NE) annotation efforts. The key strategy to achieve a semantic behaviour is to normalise NEs, i.e., linking entities to concepts in an openly available ontology, which effectively allows to map a concept with its multiple word forms. Thalia covers the entire PubMed, which at the point of this challenge contains about 27 million references. Thalia includes annotations of several types (Chemicals, Diseases, Drugs, Genes, Metabolites, Proteins, Species and Anatomic entities). 
Type Of Technology Webtool/Application 
Year Produced 2017 
Open Source License? Yes  
Impact The semantic search system has been used to support a precision medicine challenge, retrieving documents containing potential treatments and clinical trials for specific patient characteristics. 
URL http://nactem-copious.man.ac.uk/Thalia/thalia.html
 
Description 8th Culture and International Mental Health Conference 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact 8th Culture and International Mental Health Conference, part of the The South Asia Self Harm Initiative
Global Challenge Research Fund: South Asia Self Harm research capability building Initiative (GCRF-SASHI)
Year(s) Of Engagement Activity 2018
URL http://sashi.bangor.ac.uk/staff.php.en
 
Description American College of Rheumatology (November 2017, San Diego) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact We presented data on the value of troponins in predicting future CVD in early RA
Year(s) Of Engagement Activity 2017
 
Description American College of Rheumatology 2018 Conference, Chicago, USA - October 2018 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Presentation of results of work for the BRC on stratified medicine and cross-CTD immune pathogenesis shared pathways.
Year(s) Of Engagement Activity 2018
 
Description BILAG-BR Investigators Day ( December 2017, Manchester) 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact The investigator meeting trained colleagues into the study procedures for the BILAG BR study and discussed MASTERPLANS in this context
Year(s) Of Engagement Activity 2017
 
Description BRC Celebration Event (December 2016, Manchester) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact This event brought together university and hospital staff from across the city to disucss the BRC future plans and vision
Year(s) Of Engagement Activity 2016
 
Description BRC Scientific Advisory Board Meeting (January 2018) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The BRC SAB was to reflect on the initial year of the BRc and discuss strategy and receive international expert input on our short term objectives and our medium term strategy
Year(s) Of Engagement Activity 2018
 
Description BRC2 Workshop (June 2017, Manchester) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Planning meeting for next BRC in Manchester (2022)
Year(s) Of Engagement Activity 2017
 
Description CRUK-Abcodia Science Advisory Board 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact I was invited to become a member of the Science Advisory Board for collaboration between Cancer Research UK and Abcodia, the biomarker validation company. The main reason for this collaboration is to develop new tests to detect various cancers before patients develop any symptoms.
Year(s) Of Engagement Activity 2013,2014,2015,2016,2017
 
Description Cub scouts visit to the Stoller 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact 48 cub scouts aged 8-11 years old attended an evening visit to the Stoller Biomarker Discovery Centre where staff engaged in fun experiments designed to interest children in science. The feedback from the visitors has been very positive with additional visits from older scout troops planned for later in the year.
Year(s) Of Engagement Activity 2017
 
Description High profile visit from the Deputy Prime Minister and Manchester Alumni from Singapore 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact High profile visit from the Deputy Prime Minister and Manchester Alumni from Singapore on the 26th of March 2018.
Year(s) Of Engagement Activity 2018
 
Description How Precision Medicine will Transform Healthcare ( March 2018, Manchester) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact This meeting was part of our BRC seminar series and discussed precision medicine and presented exemplars of current studies
Year(s) Of Engagement Activity 2017,2018
 
Description Kellgren @ 10 Manchester (December 2017, Manchester) 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact This event was to update our patients and study participants on our research and progress with recent studies
Year(s) Of Engagement Activity 2017
 
Description Keynote Open Science Paris (December 2018) 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact I was invited to give a keynote talk at the Journées pour la science ouverte (Days for open science), in Paris, France.

These days, organised by the Comité pour la science ouverte, have been arranged following the announcement of the French national plan for open science on July 4, 2018 by the Minister of Higher Education, Research and Innovation, and were an opportunity to mobilise the scientific community around open science and applications
Year(s) Of Engagement Activity 2018
URL https://bib.cnrs.fr/journees-pour-la-science-ouverte-open-science-days-paris-december-4th-to-6th-201...
 
Description Launch of the Medicines Discovery Catapult (January 2017, Alderley Park) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact The Catapult is an important partner for our BRC and this launch event introduced us to new collaborators and potential funding streams
Year(s) Of Engagement Activity 2018
 
Description MRC group on Stratification in next 30 years 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other audiences
Results and Impact MRC group on Stratification in next 30 years
Year(s) Of Engagement Activity 2019
 
Description Machine reading for cancer biology at the Global Pharma R&D Informatics Congress 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This congress looks at new methods and new technologies that get the best out of the information available and
strategies to integrate internal and external systems so that all teams get the information they need to accelerate
the drug development pipeline. Attracting experts working in all areas of pharmaceutical R&D IT and discovery
informatics, the event focused on innovations and strategies in these 4 key topic areas:
• Complex Data Analytics
• System Integration
• AI and Machine Learning
• Data Storage and Management
Year(s) Of Engagement Activity 2017
URL http://www.global-engage.com/wp-content/uploads/2017/07/Global-Pharma-RD-Informatics-Congress-Europe...
 
Description Minute Lecture: Biomarkers 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Animated Youtube video titled "Minute Lecture: Biomarkers" that aimed to explain in a lay language what biomarkers are and how they are important to modern medicine, from the perspective of MMPathIC. The video was written and voiced by an MMPathIC member of staff and the animations were created by The University of Manchester Faculty of Biology, Medicine and Health (FBMH). The video was shared originally on the FBMH Twitter account and FBMH Youtube channel.
Year(s) Of Engagement Activity 2018
URL https://www.youtube.com/watch?v=98i7rUReD_o
 
Description NIHR BRC Workshop on Oncology Initiatives 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Other audiences
Results and Impact NIHR BRC Workshop on Oncology Initiatives
Year(s) Of Engagement Activity 2019
 
Description NIHR Manchester BRC PPI and E Training 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact I organised a BRC workshop for training on PPI and E. I opened the meeting with a talk around how the BRC prioritises PPIE and also participated in a workshop on study design and how patients can help improve study conduct and pragmatic aspects of studies.
Year(s) Of Engagement Activity 2017
 
Description NIHR Manchester BRC and CRF Newsletter (June 2017) 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Supporters
Results and Impact Our BRC newsletter is read widely by our circulation list and helps publicise our work amongst key stakeholders
Year(s) Of Engagement Activity 2017
 
Description NIHR Northern Biomedical Research Centre`s Showcase (March 2018, Manchester) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact We presented the work of the Northern BRCs to industry in an event supported by the NHSA
Year(s) Of Engagement Activity 2018
 
Description NOVARTIS Biomedical Research Foundation (June 2017, Mayfair) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact A meeting between NIHR and Novartis to discuss potential engagement of Novartis in the UK
Year(s) Of Engagement Activity 2017
 
Description Novel biosensor for lung disease 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact This was a youtube video to promote high sensitivity suspended graphene sensor using a suspended graphene array to diagnose lung disease.
Year(s) Of Engagement Activity 2018
URL https://www.youtube.com/watch?v=MITshV4XXCk&t=88s
 
Description Public engagement activity in the form of the Young Peoples lecture at the Manchester Literary and Philosophical Society 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Schools
Results and Impact Interactive lecture to the Manchester Literary and Philosophical Society with a focus on young people. The talk covered Precision Medicine and Biomarkers, predominantly molecular but touching on a wider field. It introduced the concept of Biomarkers, Big Data, Health Economics, e-Medicine and future careers in Medicine and associated areas.
Year(s) Of Engagement Activity 2017
URL https://www.manlitphil.ac.uk/event-photos
 
Description Public engagement lecture on the future of medicine as driven by molecular biomarkers 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Interactive lecture to the Hebden Bridge Literary and Scientific Society. The talk covered Precision Medicine and Biomarkers, predominantly molecular but touching on a wider field. It introduced the concept of Biomarkers, Big Data, Health Economics, e-Medicine and the future of Medicine as seen through the eyes of a patient.
Year(s) Of Engagement Activity 2018
URL http://hblitandsci.org.uk/reports/
 
Description SLE presentation to Red Ex Pharmaceuticals 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Industry/Business
Results and Impact I gave a presentation to this NW-based SME to discuss stratified medicine and chronic damage in SLE patients
Year(s) Of Engagement Activity 2018
 
Description School visit 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact 14 children visited from a local primary school and participated in child-friendly protein science experiments related to our research, supervised by teachers and lab technicians.
Year(s) Of Engagement Activity 2017
 
Description Scouts visit 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Third sector organisations
Results and Impact 30 Scouts aged 10-11 attended an evening visit to the Stoller Biomarker Discovery Centre, including different protein science experiment stations related to our research.
Year(s) Of Engagement Activity 2017
 
Description Site Visit Arthritis UK (October 2017) 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact PREVeNT RA poster was for a poster presentation at the site visit from the funding body Arthritis Research UK which took place in October 2017 our MASTERPLANS studies were also highlighted as part of our precision medicine workplans
Year(s) Of Engagement Activity 2017
 
Description TREC Precision Medicine / Clinical Decision track 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact We presented our work to support precision medicine based on the use of a biomedical semantic search engine called Thalia (Text mining for Highlighting, Aggregating and Linking Information in Articles), which has been developed at NaCTeM. The main purpose of Thalia is to enable semantic search in the context of biomedical literature by leveraging previous named entity (NE) annotation efforts, and to apply it to different use cases.
Year(s) Of Engagement Activity 2017
URL http://www.trec-cds.org/2017.html
 
Description Text Mining Workshop for Precision Medicine 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact The text mining workshop was aimed at clinical and industry colleagues who would like to attend a showcase of a number of innovative text mining approaches for biomarker discovery. There was also potential to discuss collaborative grant applications where this enabling technology will be an asset.
Year(s) Of Engagement Activity 2019
URL http://www.nactem.ac.uk/newsitem.php?item=388
 
Description The Times, supplement called Future North 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Media (as a channel to the public)
Results and Impact The Times (the supplement went into all copies of The Times in Yorkshire, North West and North East of England); a summary about importance of the Stoller Biomarker Discovery Centre in the biomarker discovery, validation and verification.
Year(s) Of Engagement Activity 2019
 
Description UK Biobank Enhancement Working Group 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact Development of a new multiomics approach on the UK Biobank cohort.
Year(s) Of Engagement Activity 2018,2019
 
Description UK Biobank's COO and Director of Operations visited Stoller Biomarker Discovery Centre 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Other audiences
Results and Impact UK Biobank's COO Mark Effingham and Director of Operations Simon Sheard visited Stoller Biomarker Centre on the 21st of November 2018 to see the facility and to discuss future collaboration with Prof. Tony Whetton.
Year(s) Of Engagement Activity 2018
 
Description Visit to China to key universities (January 2018, China) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Our university visited 4 Chinese universities. We planned and discussed future collaborations including student exchanges, collaborative grants and future visits
Year(s) Of Engagement Activity 2018
 
Description World Healthcare Conference - 5th March 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Presentation of work from NIHR BRC particularly around SLE and stratified medicine, followed by a panel discussion on stratified medicine.
Year(s) Of Engagement Activity 2019
 
Description World Precision Medicine Congress 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Presentation at the World Precision Medicine Congress describing how the MRC/EPSRC Molecular Pathology Nodes in the UK work and explaining the role of the Manchester Molecular Pathology Node in Translation of discovery biomarkers into the NHS
Year(s) Of Engagement Activity 2016
URL http://www.globaleventslist.elsevier.com/events/2016/05/world-precision-medicine-congress/